|
PI3Kα Inhibitors for the Treatment of Cancer
Application
Compounds that inhibit the kinase activity of phospoinostidie 3-kinase (PI3Kα) for the treatment of cancer.
Key Benefits
Potential therapeutic targeted to pathway without a clinically approved inhibitor.
Provides a useful pharmacological probe for research purposes.
Market Summary
In order to grow, cancer cells must have the...
Published: 4/23/2024
Contributor(s): Qi Shi, Thomas Kaiser, Dennis Liotta, James Snyder, Zackery Dentmon, John Diraddo
|
|
Assay for Non-Nucleoside Inhibitors of the Measles and Nipah Viruses
Application
A cell-based assay to screen for inhibitors of the measles virus (MV). Highly active compounds have been identified and analogs have been synthesized and evaluated.
Key Benefits
Potent (sub-nM range), non-peptidic, non-nucleosidic compounds.
Robust, cell-based, high-throughput screening assay.
Technical Summary
Vaccination serves...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun
|
|
Multi-Target CCR5/CXCR4 Chemokine Compounds for the Treatment of HIV
Application
Chemical compounds that bind to both CCR5 and CXCR4 chemokine GPCRs as therapeutics to block HIV entry and infection.
Key Benefits
Targets both chemokine receptors used for cell entry by HIV: CCR5 & CXCR4.
Eliminates the requirement of a tropism pre-test used for drug administration of single chemokine agents.
Does not interfere...
Published: 4/23/2024
Contributor(s): Bryan Cox, Lawrence (larry) Wilson, Anthony Prosser, James Snyder, Dennis Liotta
|
|
OSIRIS: An Information Management Application for Use in Drug Discovery and Development
Application
A web-based information management application for data tracking and sharing during the discovery and development of new small molecule therapeutics.
Key Benefits
Can be used to register compounds and display information about chemical structures and calculations.
Easily customizable and has a ticket system to allow administrators...
Published: 4/23/2024
Contributor(s): Serdar Kurtkaya, Iestyn Lewis, Michael Natchus, James Snyder
|
|
CXCR4 Antagonists in Treatment of Cancer
Application
Nonpeptidic molecules that block the chemokine receptor, CXCR4, for treatment of proliferative disorders including inhibition of cancer metastasis.
Key Benefits
Modulate CXCR4 receptor activity by interfering with SDF-1 ligand binding.
Inhibit migration of metastatic cancer cells by blocking chemokine receptor signaling.
Show increased...
Published: 4/23/2024
Contributor(s): Dennis Liotta, James Snyder, Weiqiang Zhan
|
|
Small Molecule Non-Nucleoside Inhibitors of the Measles Viruses
Application
Small molecule measles virus RNA Dependent RNA Polymerase (RDRP) inhibitors.
Key Benefits
Potent (nM) non-nucleoside small molecule inhibitors of the measles virus RDRP protein.
No current drug therapy for measles.
Market Summary
The target market for this therapeutic agent is in the developing world where measles has been known...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun, John Maina Ndungu, Jeong-Joong Yoon
|
|
Small Molecule Inhibitors Show Promise with RNA Viruses
Application
Potent small molecule inhibitors of RNA viruses that cause many highly contagious and dangerous diseases such as canine distemper, RSV, influenza, and measles.
Key Benefits
Inhibits measles, canine distemper, human parainfluenza, and influenza A viruses.
May be used for the management of a disease and for rapid control of possible...
Published: 4/23/2024
Contributor(s): Richard Plemper, James Snyder, Aiming Sun, John Maina Ndungu, Jeong-Joong Yoon
|
|
Triptolide Analog as Potent Anti-Inflammatory Drug Candidate
Application
Small molecule therapeutics for the treatment of inflammation and autoimmune disorders.
Key Benefits
Decreased toxicity compared to the natural product triptolide.
Improved aqueous solubility compared to triptolide.
Market Summary
Inflammation is known to be a component in a wide range of disease states including arthritis, asthma,...
Published: 4/23/2024
Contributor(s): Hariharan Venkatesan, James Snyder, Dennis Liotta, Susheng Wang
|